Lucina Biotherapeutics

Lucina Biotherapeutics is a preclinical-stage biotech founded in 2022, pioneering a novel approach to treating aging-related diseases by restoring declining levels of Very Long Chain Poly-Unsaturated Fatty Acids (VLC-PUFAs). The company's core asset is the PUFActive platform, which includes both intravitreal and oral drug delivery modalities, with its lead program LUC-101 for dry AMD in IND-enabling studies. Led by an experienced team with backgrounds in ophthalmology, drug development, and synthetic biology, Lucina is positioned to address a significant unmet need in large markets like dry AMD, where no approved therapies exist.

PUFActive Platform: A proprietary therapeutic platform designed to restore youthful levels of Very Long Chain Poly-Unsaturated Fatty Acids (VLC-PUFAs) in aging tissues. It includes two modalities: 1) synthetic VLC-PUFA formulations for targeted delivery (e.g., intravitreal) and 2) engineered microbial 'biofactories' for oral administration to systemically replenish lipids.

In dry AMD, Lucina will compete against numerous late-stage programs targeting complement inhibition, inflammation, and geographic atrophy (e.g., Apellis, Iveric Bio/Astellas, Alexion). Its lipid-replenishment mechanism is distinct, offering a differentiated approach. In the broader aging space, it competes with other geroscience companies targeting hallmarks of aging like senescence, mitochondrial function, and epigenetic regulation.